There are a lot of vague statements in that press release
I typically have the opposite view of the big pharma companies. I have seen multiple times where they massage trial data to look better than it really is.
As for this PR, they didn't state what the antibody levels were, how much higher the levels were compared to the "typical" infected person, and what is their "typical" antibody level baseline? The last one is especially important because antibody levels are very different at various points in time after onset of symptoms (so they could be making this sound much better than it really is).
In the end, they are only in Phase 1 safety study mode right now so it is far too early to put any weight behind effectiveness results. And that goes for all vaccine developers who are still in the early Phase 1 work.
|
(
In response to this post by Hokie360)
Posted: 07/01/2020 at 09:45AM